| Code | CSB-RA025141MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to CM-326, designed to specifically target thymic stromal lymphopoietin (TSLP), a key epithelial-derived cytokine that plays a critical role in initiating and amplifying allergic inflammatory responses. TSLP is primarily expressed by epithelial cells at barrier surfaces and acts on multiple immune cell types, including dendritic cells, T cells, and mast cells, to promote type 2 immune responses. Dysregulated TSLP expression has been implicated in the pathogenesis of various allergic and inflammatory conditions, including asthma, atopic dermatitis, chronic obstructive pulmonary disease, and eosinophilic esophagitis, making it an important therapeutic target in these disorders.
CM-326 represents a therapeutic antibody developed to neutralize TSLP activity and has been investigated in clinical studies for allergic diseases. This biosimilar provides researchers with a valuable tool for investigating TSLP-mediated signaling pathways, studying the role of TSLP in disease models, and exploring potential therapeutic interventions in allergic and inflammatory research. The antibody enables detailed examination of TSLP biology and its contributions to immune dysregulation.
There are currently no reviews for this product.